In this way, the current AD therapies comprise mainly cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists that could both provide enhanced quality of life by improving AD-nondependent physiological processes rather than disease progression inhibition [9]. The gene discussed is BCHE; the disease is Alzheimer disease.